Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
UBS
Julphar
Cipla
Moodys
Federal Trade Commission
McKesson
US Army
Fuji

Generated: May 22, 2018

DrugPatentWatch Database Preview

Eprosartan mesylate; hydrochlorothiazide - Generic Drug Details

or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for eprosartan mesylate; hydrochlorothiazide and what is the scope of eprosartan mesylate; hydrochlorothiazide patent protection?

Eprosartan mesylate; hydrochlorothiazide
is the generic ingredient in one branded drug marketed by Abbvie and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are eleven drug master file entries for eprosartan mesylate; hydrochlorothiazide. One supplier is listed for this compound.
Summary for eprosartan mesylate; hydrochlorothiazide
Pharmacology for eprosartan mesylate; hydrochlorothiazide

US Patents and Regulatory Information for eprosartan mesylate; hydrochlorothiazide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie TEVETEN HCT eprosartan mesylate; hydrochlorothiazide TABLET;ORAL 021268-001 Nov 1, 2001 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Abbvie TEVETEN HCT eprosartan mesylate; hydrochlorothiazide TABLET;ORAL 021268-002 Nov 1, 2001 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for eprosartan mesylate; hydrochlorothiazide

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie TEVETEN HCT eprosartan mesylate; hydrochlorothiazide TABLET;ORAL 021268-002 Nov 1, 2001 ➤ Sign Up ➤ Sign Up
Abbvie TEVETEN HCT eprosartan mesylate; hydrochlorothiazide TABLET;ORAL 021268-001 Nov 1, 2001 ➤ Sign Up ➤ Sign Up
Abbvie TEVETEN HCT eprosartan mesylate; hydrochlorothiazide TABLET;ORAL 021268-002 Nov 1, 2001 ➤ Sign Up ➤ Sign Up
Abbvie TEVETEN HCT eprosartan mesylate; hydrochlorothiazide TABLET;ORAL 021268-001 Nov 1, 2001 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
QuintilesIMS
Baxter
UBS
US Department of Justice
Queensland Health
Chinese Patent Office
Merck
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.